MD&A sentences
Green marks more positive language; red marks more negative language.
neutral · -0.037
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS The following is a discussion and analysis of the financial condition of AbbVie Inc.
neutral · -0.023
(AbbVie or the company) as of June 30, 2026 and December 31, 2025 and the results of operations for the three and six months ended June 30, 2026 and 2025.
positive · +0.532
This commentary should be read in conjunction with the Condensed Consolidated Financial Statements and accompanying notes appearing in Item 1, “Financial Statements and Supplementary Data.” EXECUTIVE OVERVIEW Company Overview AbbVie is a global, diversified research-based biopharmaceutical company positioned for success with a comprehensive product portfolio that has leadership positions across immunology, neuroscience, oncology and aesthetics.
positive · +0.690
AbbVie uses its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases.
neutral · +0.029
AbbVie's products are generally sold worldwide directly to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies and independent retailers from AbbVie-owned distribution centers and public warehouses.
neutral · +0.023
Certain products (including aesthetic products and devices) are also sold directly to physicians and other licensed healthcare providers.
neutral · +0.025
In the United States (U.S.), AbbVie distributes pharmaceutical products principally through independent wholesale distributors, with some sales directly to retailers, pharmacies, patients or other customers.
neutral · +0.070
Outside the United States, AbbVie sells products primarily to wholesalers or through distributors, and depending on the market works through largely centralized national payer systems to agree on reimbursement terms.
neutral · +0.027
Certain products are co-marketed or co-promoted with other companies.
neutral · +0.034
AbbVie operates as a single global business segment.
positive · +0.824
2026 Strategic Objectives AbbVie's mission is to discover and develop innovative medicines and products that solve serious health issues today and address the medical challenges of tomorrow while achieving top-tier financial performance through outstanding execution.
positive · +0.896
AbbVie intends to execute its strategy and advance its mission in a number of ways, including: (i) maximizing the benefits of a diversified revenue base with multiple long-term growth drivers; (ii) leveraging AbbVie's commercial strength and international infrastructure across therapeutic areas and ensuring strong commercial execution of new product launches as well as continued investment in key on-market products; (iii) continuing to invest in and expand its pipeline in support of opportunities in immunology, neuroscience, oncology and aesthetics as well as new sources of growth such as obesity; (iv) generating substantial operating cash flows to support investments in innovative research and development and returning cash to shareholders via a strong and growing dividend while maintaining a strong investment grade credit rating.
neutral · +0.407
In addition, AbbVie anticipates several regulatory submissions, approvals and data readouts from key clinical trials in the next 12 months.
neutral · +0.123
Financial Results The company's financial performance for the six months ended June 30, 2026 included delivering worldwide net revenues of $32.0 billion, operating earnings of $10.4 billion, diluted earnings per share of $2.42 and cash flows from operations of $7.3 billion.
positive · +0.941
Worldwide net revenues increased 11% on a reported basis and 10% on a constant currency basis.
neutral · -0.014
Financial results for the six months ended June 30, 2026 also included the following costs: (i) $3.4 billion related to the amortization of intangible assets; and (ii) $3.9 billion for the change in fair value of contingent consideration liabilities.
positive · +0.928
Additionally, financial results reflected continued funding to support all stages of AbbVie's pipeline assets and continued investment in AbbVie's on-market brands.
positive · +0.863
Recent Events Regulatory Environment In January 2026, AbbVie announced a voluntary agreement with the U.S.
positive · +0.889
government to further advance access and affordability of AbbVie's products in the U.S.
positive · +0.813
AbbVie will provide low prices in Medicaid and expand affordable, direct-to-patient offerings.
positive · +0.624
Additionally, AbbVie pledged $100 billion in U.S.-based research and development and capital investments, including manufacturing, over the next decade.
positive · +0.837
government has agreed to provide AbbVie a three-year exemption from tariffs and future price mandates.
neutral · +0.265
The Inflation Reduction Act of 2022 has and will continue to have a significant impact on AbbVie's business.
neutral · +0.259
Department of Health and Human Services, through Centers for Medicare and Medicaid Services, selected Botox as one of 15 medicines subject to government-set prices in Medicare Parts B and D beginning in 2028.
positive · +0.718
Capital Investment In 2026, AbbVie announced an investment to build a pharmaceutical manufacturing campus in North Carolina.
neutral · +0.471
The campus will integrate advanced manufacturing and laboratory technologies with artificial intelligence to support the production of immunology, neuroscience and oncology medicines.
positive · +0.734
Additionally, AbbVie announced investments to add two new manufacturing facilities in Illinois to support next generation neuroscience and obesity medications as well as an agreement to acquire a device manufacturing facility in Arizona, which closed in July 2026.
neutral · +0.144
These projects are part of AbbVie's plan to invest in the U.S.
positive · +0.845
to broadly support innovation and expand critical manufacturing capabilities and capacity.
neutral · +0.144
Research and Development Research and innovation are the cornerstones of AbbVie's business as a global biopharmaceutical company.
neutral · +0.299
AbbVie's long-term success depends to a great extent on its ability to continue to discover and develop innovative products and acquire or collaborate on compounds currently in development by other biotechnology or pharmaceutical companies.
neutral · +0.093
AbbVie's pipeline currently includes approximately 90 compounds, devices or indications in development individually or under collaboration or license agreements.
neutral · +0.053
Of these programs, approximately 60 are in mid- and late-stage development.
neutral · +0.044
The company's pipeline is focused on immunology, neuroscience, oncology and aesthetics as well as other specialties, including obesity.
neutral · +0.009
The following sections summarize transitions of significant programs from mid-stage development to late-stage development as well as developments in significant late-stage and registrational programs.
positive · +0.512
AbbVie expects multiple mid-stage programs to transition into late-stage programs in the next 12 months.
positive · +0.869
Significant Programs and Developments Immunology Skyrizi • In February 2026, AbbVie announced positive topline results from the Phase 3 AFFIRM trial evaluating Skyrizi subcutaneous induction in adult patients with moderately to severely active Crohn's disease (CD).
neutral · +0.363
• In April 2026, AbbVie announced the submission of an application to the U.S.
positive · +0.774
Food and Drug Administration (FDA) for Skyrizi for subcutaneous induction for the treatment of adult patients with moderately to severely active CD.
positive · +0.845
• In June 2026, AbbVie announced the European Commission (EC) approved Skyrizi for the treatment of children six years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.